Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05942222
Other study ID # 2022-ENT-3
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date April 27, 2023
Est. completion date January 2026

Study information

Verified date July 2023
Source Rigshospitalet, Denmark
Contact Christian Pedersen, MD
Phone +4525301186
Email christian.korsgaard.pedersen.01@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this randomized clinical trial is to compare the effects of two newly available biological drugs for the treatment of severe chronic rhinosinusitis with nasal polyps in Danish patients. The main questions it aims to answer are whether the two drugs are comparable in effect after 24 weeks in terms of: - A subjective score (the SNOT-22) - An objective score, i.e.the physician-assessed score of nasal polyp size (the Nasal Polyp Score (0-8)) Methods: Participants will be randomized into two groups and receive either drug in the standard dose. After 24 weeks the effect is assessed. If the clinical effect is sufficient in terms of the criteria set by the Danish Medicinal Council (see elsewhere), treatment continues with the same drug for an additional 24 weeks. If the effect criteria are not met, the subject crosses-over to the opposite drug for an additional 24 weeks. After 48 weeks the effect is assessed once more.


Description:

Objectives: - The primary objective is to compare the efficacy of mepolizumab versus dupilumab on objective and subjective symptoms of CRSwNP and related comorbidities in an attempt to determine non-inferiority between the two, or possibly; superiority of dupilumab over mepolizumab. - The secondary objective is to explore any other relevant differences between mepolizumab and dupilumab in terms of frequency of AEs, need for rescue treatments, diversity in outcome based on endotype or comorbidity or other factors, that can lead to a patient-centred approach, when choosing treatment for CRSwNP. Trial design: A randomized, multi-center non-inferiority trial (phase IV RCT). The trial is unblinded. Investigational medicinal products (IMPs) will be "off-the-shelf" and administered in standard dosages and -intervals. Trial population: The trial aims to include 220 patients with severe, uncontrolled CRSwNP (110 patients in each treatment group). The patients will be recruited from 9 different sites all across Denmark. Treatment in Denmark is 100% subsidized by the state. Methods: Subjects fulfilling inclusion criteria will be randomized 1:1 to either dupilumab or mepolizumab. After 24 weeks a halfway evaluation will decide if subjects are to stay in their current treatment arm, or cross-over to the opposite arm. By including 220 participants (effectively 176 participants after 20% drop-outs) the study will achieve a power of >95% to show non-inferiority of dupilumab to mepolizumab for both co-primary endpoints with the following criteria: Level of significance for both endpoints of a one-sided test, p<0.025 and including previously found standard deviation (SD) values 1.9 for NPS and 22 for SNOT-22, an expected superior effect of 0.7 for NPS and 7 on SNOT-22, a minimal clinically relevant difference (MCID) of 1 for NPS and 12 for SNOT-22, respectively. Trial medication: All trial medication will be "off the shelf" i.e. no special labelling. It will be provided by hospital pharmacies in accordance with GMP. The investigational medicinal products (IMPs) are dupilumab (Dupixent, Sanofi) and mepolizumab (Nucala, GSK). Dupilumab are given as subcutaneous injections of 300 mg every two weeks in the first 24 weeks. If the DMC response criteria (table 2) are met after 24 weeks, the dosing interval will be increased to every four weeks, in accordance with previous research. Mepolizumab is administered subcutaneously as 100 mg sc. every four weeks. Patients will continue basic treatment of INCS and saline irrigation, unless contraindicated. If rescue treatment is needed, a course of oral corticosteroids (Prednisolone) 37.5 mg once daily for 7 days will be given. Trial schedule: Planned first subject first visit May 2023 Planned last subject randomized May 2024 Planned last subject last visit: June 2025 End of trial October 2025


Recruitment information / eligibility

Status Recruiting
Enrollment 220
Est. completion date January 2026
Est. primary completion date October 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Bilateral polyps in nose and sinuses - ESS within the last three years (unless unfit for surgery y- in this study defined as either a severe somatic disease, for which other specialist advise against surgery, e.g., cardiac disease, pulmonary disease, or coagulation disorder OR/AND severe anxiety which can either be due to previous traumatic experiences with surgery or the postoperative period, post-traumatic stress disorder or severe anxiety disorder. In cases of doubt, investigators can ask for a written statement from the general practitioner or a psychiatrists/psychologist)) - Optimal local treatment with saline irrigation and topical nasal steroids for at least three months (unless contraindicated) - Evidence of type 2 inflammation Furthermore, patients must fulfil three out the following five criteria: - Need for systemic corticosteroids (at least two courses/year OR long-term treatment >3 months) or contraindication to systemic steroids - Significantly impaired QoL (SNOT-22 score=50) - Significant LoS (SSIT-16 score 0-8) - NPS =5 (with at least 2 on either side) - Asthma diagnosis (requiring inhaled corticosteroid (ICS)) Also: Age of 18 years or more and able to read and/or speak Danish Exclusion criteria - Systemic corticosteroid treatment within the last three months - Endoscopic sinus surgery (ESS) within the last six months - Non-adherent to medicine regimens - Hypersensitivity to the active substance or any of the excipients in the two IMPs - Not able to understand spoken and/or written Danish - Participation-current or previous (within the last year)-in another investigational drug trial with monoclonal antibodies for asthma, CRSwNP, atopic dermatitis or allergic rhinitis. - Pronounced fear of needles - Pregnant or breastfeeding patients

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
dupilumab
Subcutaneus injections in standard doses, i.e. 300 mg s.c. every 2 weeks.
mepolizumab
Subcutaneus injections in standard doses, i.e. 100 mg s.c. every 4 weeks.

Locations

Country Name City State
Denmark Aalborg Universitetssygehus Syd Aalborg
Denmark Aarhus Universitetshospital Skejby Aarhus
Denmark Rigshospitalet Copenhagen
Denmark Sydvestjysk Sygehus Esbjerg Esbjerg
Denmark Regionshospitalet Gødstrup Herning
Denmark Nordsjællands Hospital Hillerød
Denmark Sjællands Universitetshospital Køge Køge
Denmark Odense Universitetshospital Odense
Denmark Sygehus Lillebælt Vejle Vejle

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary SNOT-22 Sino-Nasal Outcome Test 22 - change in score since baseline is measured. Week 24
Primary NPS Nasal Polyp Score (0-8): 0 is no polyps, 4 is polyps extending below inferior turbinate's lower border. Each side is scored. The change in score at week 24 since baseline is measured. Week 24
Secondary SNOT-22 Sino-Nasal Outcome Test 22 - change in score since week 24 and week 0 if applicable Week 48
Secondary NPS Nasal Polyp Score (0-8): 0 is no polyps, 4 is polyps extending below inferior turbinate - lower border. Each side is scored. Change in score since week 24 and week 0 if applicable Week 48
Secondary Smell score (Sniffin' Sticks Identification Test-16- SSIT-16) Change since baseline in SSIT-16 (range 0-16, where 0-8 is anosmia) Week 48
Secondary Asthma control (Asthma Control Questionnaire) Proportion of patients with ACQ score > 0,5 indicating well-controlled asthma. Week 48
Secondary Nasal Congestion Score (NCS) Range 0-3. Change since baseline Week 48
Secondary Visual Analogue Scale of: smell/asthma/Chronic rhinosinusitis/N-ERD Change in VAS-score (range 0-10) since baseline Week 48
Secondary Proportion meeting the evaluation criteria set by the DMC The DMC criteria is available at medicinraadets website medicinraadet.dk Week 48
Secondary Fraction of Nitrous Oxide in expired air (FeNO) A score above 25 indicates eosinophilic inflammation. Week 48
Secondary Proportion needing rescue treatment A rescue treatment is defined as systemic oral corticoids or endoscopic sinus surgery. Week 48
See also
  Status Clinical Trial Phase
Recruiting NCT05895929 - The Role of IL5 in Epithelial Cell Integrity Early Phase 1
Recruiting NCT05891483 - Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps Phase 2
Recruiting NCT04998604 - EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients Phase 4
Recruiting NCT06069310 - Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
Recruiting NCT05009758 - Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps N/A
Active, not recruiting NCT05529784 - Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL)
Recruiting NCT05902325 - Identifying Predictors Of Response To Mepolizumab In CRSwNP Phase 4
Completed NCT05049122 - Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52) Phase 4
Not yet recruiting NCT05598411 - CST1-Guided Oral Glucocorticoids Management for CRSwNP Phase 4
Active, not recruiting NCT05553951 - Adherence in Global Airways N/A
Recruiting NCT05131464 - The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps Phase 2
Recruiting NCT05598424 - CST1 Predictive Model of Oral Glucocorticoid Therapy Sensitivity for Chronic Rhinosinusitis With Polyps Phase 4
Active, not recruiting NCT05649813 - A Study in Male and Female Adult Participants With Chronic Rhinosinusitis With Nasal Polyps In the Greater Gulf Region
Recruiting NCT04628442 - Tissue Immune Interaction in Nasal Polyposis
Active, not recruiting NCT06118554 - 3D Printing to Improve Nasal Irrigation Outcome N/A
Active, not recruiting NCT04596189 - Dupilumab for Prevention of Recurrence of CRSwNP After ESS Phase 4
Recruiting NCT02668861 - Effect of Oral Vitamin D3 on Chronic Rhinosinusitis Treatment in Adults With Lower Vitamin D Levels Phase 3
Active, not recruiting NCT05878093 - Dupilumab in Chinese Adult Participants With CRSwNP Phase 3
Not yet recruiting NCT06398873 - Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP
Completed NCT05931744 - The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis Phase 2/Phase 3